Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab Long-term Extension in Rheumatoid Arthritis
NCT04333147Phase 3Terminated
- Sponsor
- GSK
- Start
- May 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of otilimab in rheumatoid arthritis (RA), sponsored by GSK. Started May 2020; status: terminated.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04333147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333147.